Janux Therapeutics (JANX) Capital Expenditures (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Capital Expenditures data on file, last reported at $273000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures rose 396.74% year-over-year to $273000.0 in Q1 2026; TTM through Mar 2026 was $89000.0, a 3.49% increase from a year earlier, with the FY2025 full-year figure at -$276000.0, down 173.6% from the prior year.
• Capital Expenditures for Q1 2026 stood at $273000.0, up from -$1.2 million in the prior quarter.
• Over the last five years, Capital Expenditures for JANX reached as high as $1.5 million in Q2 2022 and fell as low as -$1.2 million in Q4 2025.
• Historically, Capital Expenditures has averaged $205411.8 across 5 years, with a median of $285000.0 in 2023.
• Across the five-year window, Capital Expenditures tumbled 891.3% in 2022 and surged 885.26% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $313000.0 in 2022, then jumped by 64.54% to $515000.0 in 2023, then plunged by 35.34% to $333000.0 in 2024, then tumbled by 464.26% to -$1.2 million in 2025, then soared by 122.51% to $273000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $273000.0 in Q1 2026, -$1.2 million in Q4 2025, and $93000.0 in Q3 2025.